Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued on Friday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

ADXS opened at $0.06 on Friday. Ayala Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $1.49. The firm has a market capitalization of $2.45 million, a P/E ratio of -0.01 and a beta of 1.72. The company’s 50-day moving average is $0.04 and its 200 day moving average is $0.19.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.